Frontiers in Immunology, 2018 The aberrant expression of human endogenous retrovirus (HERV) elements of the HERV-W family has been associated with different diseases, including multiple sclerosis (MS).
Benjamin Charvet +6 more
doaj +2 more sources
Low CD46 expression on activated CD4+ T cells predict improved Th1 cell reactivity to calcitriol in majority of patients with allergic eosinophilic asthma and healthy donors [PDF]
Frontiers in AllergyBackgroundPrevious research showed that the intracellular complement system, with CD46 as its central molecule, regulates the Th1 response associated with IFN-γ production and transition to a type 1 regulatory response (Tr1) characterized by IL-10 ...
Julie Stichova +12 more
doaj +2 more sources
Association Between Promoter Polymorphisms in CD46 and CD59 in Kidney Donors and Transplant Outcome
Frontiers in Immunology, 2018 Complement regulating proteins, including CD46, CD55, and CD59, protect cells against self-damage. Because of their expression on the donor endothelium, they are hypothesized to be involved in accommodation.
Laura A. Michielsen +4 more
doaj +2 more sources
The outer membrane protein, OMP71, of Riemerella anatipestifer, mediates adhesion and virulence by binding to CD46 in ducks [PDF]
Veterinary ResearchThe Riemerella anatipestifer bacterium is known to cause infectious serositis in ducklings. Moreover, its adherence to the host’s respiratory mucosa is a critical step in pathogenesis.
Yanhua Wang +13 more
doaj +2 more sources
CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment
bioRxiv, 2023 We recently identified CD46 as a novel prostate cancer cell surface antigen that shows lineage independent expression in both adenocarcinoma and small cell neuroendocrine subtypes of metastatic castration resistant prostate cancer (mCRPC), discovered an ...
Jun Li +18 more
semanticscholar +1 more source
Immunologic and Genetic Contributors to CD46-Dependent Immune Dysregulation
Journal of Clinical Immunology, 2023 Mutations in CD46 predispose to atypical hemolytic uremic syndrome (aHUS) with low penetrance. Factors driving immune-dysregulatory disease in individual mutation carriers have remained ill-understood.
Benedikt J. Meyer +22 more
semanticscholar +1 more source
CD46–ADC Reduces the Engraftment of Multiple Myeloma Patient-Derived Xenografts
Cancers, 2023 Simple Summary Multiple myeloma (MM) is incurable, implying that the disease cells are inherently resistant to current agents and inevitably lead to relapse.
Michael J. VanWyngarden +9 more
semanticscholar +1 more source
CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma
Clinical Cancer Research, 2023 Purpose: Multiple myeloma is a plasma cell malignancy with an unmet clinical need for improved imaging methods and therapeutics. Recently, we identified CD46 as an overexpressed therapeutic target in multiple myeloma and developed the antibody YS5, which
Anju Wadhwa +22 more
semanticscholar +1 more source
Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy
bioRxiv, 2022 Radiopharmaceutical therapy is changing the standard of care in prostate cancer (PCa) and other malignancies. We previously reported high CD46 expression in PCa and developed an antibody-drug conjugate and immunoPET agent based on the YS5 antibody, which
A. Bidkar +22 more
semanticscholar +1 more source
CD46 Genetic Variability and HIV-1 Infection Susceptibility
Cells, 2021 CD46 is the main receptor for complement protein C3 and plays an important role in adaptive immune responses. CD46 genetic variants are associated with susceptibility to several infectious and autoimmune diseases.
Carmen Serrano-Rísquez +12 more
doaj +1 more source